Johnson & Johnson , right before the market opened on Tuesday 13, October, showed off its earnings numbers for the three months through September. Earnings for the quarter came in at $1.49. The firm showed sales totaling $17.1B for the three months.
In the run up to the release of today’s results, analysts following the firm were looking for earnings per share of $1.44 from Johnson & Johnson for the quarter. Sales for the period were forecast to come in at $17.41 by consensus.
Johnson & Johnson results by comparison
The same three months of 2014 saw Johnson & Johnson earn $1.66 on sales that came to $18,45B. In the last twelve months shares in the firm have lost 5.9% of their value in the last twelve month. In the three months leading into the release of these results the firm lost 4.54%
Johnson & Johnson
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices.
Analysts look at Johnson & Johnson
Johnson & Johnson is expected to make a profit of $1.49 per share for the twelve months of its current fiscal year. Full sales for the year are forecast to come in at $70.57B.
In the last full fiscal year, Johnson & Johnson gain $1.49 Annual EPS]. Sales came in at $17.1B
Of the 19 analysts covering the firm for Wall Street, 5 analysts said that clients should Buy shares in the firm, 4 analysts rated the shares at Overweight, while 9 analysts said that holding the shares was the best option going forward.
1 analyst said that clients should keep the shares Underweight in their portfolios, while none said that their best idea was to Sell the shares ahead of the release of this earnings report.